+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Pain Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 140 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960390

Cancer Pain Market Overview

The cancer pain market size was valued at USD 6.53 billion in 2023, driven by increasing cancer incidence and rising demand for effective therapeutics to manage cancer pain across the 8 major markets. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2024-2032, with the values likely to rise from USD 6.9 billion in 2024 to USD 10.66 billion by 2032.

Cancer pain is a complex and multidimensional symptom that affects the quality of life of cancer patients. Cancer pain can be caused by the tumor itself, the treatments, or the side effects of the treatments. Cancer pain can be acute or chronic, and can vary in intensity, frequency, and duration. The management of cancer pain involves a multidisciplinary approach that includes pharmacological and non-pharmacological interventions, such as opioids, non-opioids, adjuvants, nerve blocks, radiotherapy, surgery, psychological therapies, and complementary therapies.

Cancer Pain Market Drivers and Constraints

The key drivers of the global cancer pain market are:

  • The increasing prevalence and incidence of cancer worldwide, especially in the aging population.
  • The rising awareness and demand for effective pain management among cancer patients and caregivers.
  • The development and launch of novel and innovative products, such as extended-release formulations, transdermal patches, and abuse-deterrent formulations, that offer better efficacy, safety, and convenience.
  • The expansion of the indications and the patient population for existing products, such as opioids, adjuvants, and cannabinoids.
  • The favorable reimbursement policies and government initiatives that support the access and affordability of cancer pain treatments.

The key constraints of the global cancer pain market are:

  • The high cost and low availability of some of the cancer pain treatments, especially in the developing and underdeveloped regions.
  • The stringent regulatory requirements and the long approval process for new products and indications.
  • The lack of standardized guidelines and protocols for cancer pain assessment and management across different regions and settings.
  • The low awareness and education among healthcare professionals and patients about the optimal use of cancer pain treatments.
  • The social stigma and legal barriers associated with some of the cancer pain treatments, such as opioids and cannabinoids.

Cancer Pain Market Trends and Developments

  • Increasing Incidence of Cancer: The rising global incidence of cancer is leading to a greater number of patients requiring pain management, thereby driving the demand for cancer pain treatments.
  • Advancements in Pain Management Therapies: There is ongoing research and development of new analgesics, including non-opioid medications, targeted therapies, and combination treatments, to provide more effective and safer options for cancer pain management.
  • Shift Towards Personalized Medicine: Personalized pain management approaches, based on the genetic makeup of patients and the specific characteristics of their cancer, are being explored to optimize treatment outcomes.
  • Integration of Multimodal Approaches: The trend towards multimodal pain management, which combines pharmacological and non-pharmacological therapies (such as physical therapy, acupuncture, and psychological support), is gaining traction for a more holistic approach to cancer pain.
  • Focus on Quality of Life: There is an increasing emphasis on assessing and improving the quality of life for cancer patients, with pain management being a crucial aspect of palliative care.
  • Use of Advanced Drug Delivery Systems: Innovations in drug delivery systems, such as transdermal patches, implantable pumps, and extended-release formulations, are improving the efficacy and convenience of cancer pain treatments.
  • Growing Awareness and Education: Efforts to raise awareness among healthcare professionals and patients about effective cancer pain management strategies are contributing to better pain control and treatment adherence.
  • Regulatory Challenges and Opioid Concerns: The opioid crisis has led to stricter regulations and guidelines for prescribing opioid analgesics, impacting the cancer pain market and necessitating the development of alternative pain management options.

Cancer Pain Market Segmentation

Market Breakup by Drug Type 

  • Opioids
  • Fentanyl
  • Morphine
  • Others
  • Non-Opioids 
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drug
  • Nerve Blockers

Market Breakup by Indication Type

  • Lung Cancer 
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others 

Market Breakup by Treatment Type

  • Immunotherapy  
  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Cancer Pain Market: Competitive Landscape

The market report encompasses comprehensive analyses, including patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, as well as partnerships and collaborations analysis conducted by the leading key players in the market. Among the major companies contributing to this market are Eli Lilly, HISAMITSU PHARMACEUTICAL CO., INC., Aoxing Pharmaceutical Company, Inc., GRÜNENTHAL PHARMA GmbH & CO. KG, PFIZER INC., BIODELIVERY SCIENCES INTERNATIONAL, INC., OREXO AB, Johnson and Johnson, Medtronic plc, Novartis AG, and Glaxo SmithKline Plc. These analyses and the involvement of these prominent players highlight the dynamic and evolving nature of the market, underlining the significant investments and collaborations driving advancements and growth in the field.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Pain Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Pain Epidemiology Analysis - 8MM
5.1 8MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Cancer Pain Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
5.3.1 Germany Cancer Pain Epidemiology Forecast (2017-2032)
5.3.2 France Cancer Pain Epidemiology Forecast (2017-2032)
5.3.3 Italy Cancer Pain Epidemiology Forecast (2017-2032)
5.3.4 Spain Cancer Pain Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
5.4 Japan Cancer Pain Epidemiology Forecast (2017-2032)
5.5 India Cancer Pain Epidemiology Forecast (2017-2032)
6 Cancer Pain Market Overview - 8MM
6.1 Cancer Pain Market Historical Value (2017-2023)
6.2 Cancer Pain Market Forecast Value (2024-2032)
7 Cancer Pain Market Landscape - 8MM
7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cancer Pain Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Indication Type
7.2.3 Analysis by Treatment Type
8 Cancer Pain Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Cancer Pain Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Cancer Pain Market Segmentation - 8MM
11.1 Cancer Pain Market by Drug Type
11.1.1 Market Overview
11.1.2 Opioids
11.1.2.1 Fentanyl
11.1.2.2 Morphine
11.1.2.3 Others
11.1.3 Non-Opioids
11.1.3.1 Acetaminophen
11.1.3.2 Non-Steroidal Anti-Inflammatory Drugs
11.1.4 Nerve Blockers
11.2 Cancer Pain Market by Indication Type
11.2.1 Market Overview
11.2.2 Lung Cancer
11.2.3 Colorectal Cancer
11.2.4 Breast Cancer
11.2.5 Prostate Cancer
11.2.6 Blood Cancer
11.2.7 Others
11.3 Cancer Pain Market by Treatment Type
11.3.1 Market Overview
11.3.2 Immunotherapy
11.3.3 Chemotherapy
11.3.4 Targeted Therapy
11.3.5 Hormonal Therapy
11.4 Cancer Pain Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Cancer Pain Market
12.1 Cancer Pain Market Historical Value (2017-2023)
12.2 Cancer Pain Market Forecast Value (2024-2032)
12.3 Cancer Pain Market by Drug Type
12.4 Cancer Pain Market by Indication Type
13 EU-4 and United Kingdom Cancer Pain Market
13.1 Cancer Pain Market Historical Value (2017-2023)
13.2 Cancer Pain Market Forecast Value (2024-2032)
13.3 Germany Cancer Pain Market Overview
13.3.1 Cancer Pain Market by Drug Type
13.3.2 Cancer Pain Market by Indication Type
13.4 France Cancer Pain Market Overview
13.4.1 Cancer Pain Market by Drug Type
13.4.2 Cancer Pain Market by Indication Type
13.5 Italy Cancer Pain Market Overview
13.5.1 Cancer Pain Market by Drug Type
13.5.2 Cancer Pain Market by Indication Type
13.6 Spain Cancer Pain Market Overview
13.6.1 Cancer Pain Market by Drug Type
13.6.2 Cancer Pain Market by Indication Type
13.7 United Kingdom Cancer Pain Market Overview
13.7.1 Cancer Pain Market by Drug Type
13.7.2 Cancer Pain Market by Indication Type
14 Japan Cancer Pain Market
14.1 Cancer Pain Market Historical Value (2017-2023)
14.2 Cancer Pain Market Forecast Value (2024-2032)
14.3 Cancer Pain Market by Drug Type
14.4 Cancer Pain Market by Indication Type
15 India Cancer Pain Market
15.1 Cancer Pain Market Historical Value (2017-2023)
15.2 Cancer Pain Market Forecast Value (2024-2032)
15.3 Cancer Pain Market by Drug Type
15.4 Cancer Pain Market by Indication Type
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 India CDSCO
16.1.4 JAPAN PMDA
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnerships and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Eli Lilly
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 HISAMITSU PHARMACEUTICAL CO., INC.,
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Aoxing pharmaceutical company, inc.,
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 GRÜNENTHAL PHARMA GmbH & CO. KG
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 PFIZER INC.,
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 BIODELIVERY SCIENCES INTERNATIONAL, INC.,
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 OREXO AB
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Johnson and Johnson
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Medtronic plc
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Novartis AG
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Glaxo SmithKline Plc
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
23 Cancer Pain Market- Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Eli Lilly
  • HISAMITSU PHARMACEUTICAL CO. Inc.
  • Aoxing pharmaceutical company Inc.
  • GRÜNENTHAL PHARMA GmbH & CO. KG
  • PFIZER INC.
  • BIODELIVERY SCIENCES INTERNATIONAL Inc.
  • OREXO AB
  • Johnson and Johnson Medtronic plc
  • Novartis AG
  • Glaxo SmithKline Plc

Methodology

Loading
LOADING...